RxDoctor Payments Data

Carol Young, MD

Pulmonary Disease · Shallotte, NCNPI 1124005897

Payments from drug & device makers

$1,746in general payments, 2019–2025

Across 83 payments — averaging $21.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$289
  • Insmed, Inc.$185
  • Baxter Healthcare$175
  • Sanofi$151
  • Amgen$148
  • GSK$147
  • plus $652 from 14 others

What the payments were for

  • Food & beverage$1,746100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,746 in reported general payments places this provider in the 50th percentile of 393 pulmonary disease providers in North Carolina.

See all pulmonary disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$105,305
Medicare patients
430
Services billed
1,113

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter179$142,716
OpsumitMacitentan11$137,409
OfevNintedanib Esylate11$133,337
Breztri AerosphereBudesonide/Glycopyr/Formoterol142$95,616
Breo ElliptaFluticasone/Vilanterol66$29,857
Advair HfaFluticasone Propion/Salmeterol54$24,157
Spiriva RespimatTiotropium Bromide34$22,682
SymbicortBudesonide/Formoterol Fumarate77$20,145
Incruse ElliptaUmeclidinium Bromide23$10,342
Fluticasone-SalmeterolFluticasone Propion/Salmeterol42$8,138
Wixela InhubFluticasone Propion/Salmeterol60$6,778
Arnuity ElliptaFluticasone Furoate24$5,917
Albuterol Sulfate HfaAlbuterol Sulfate157$5,673
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate35$4,837
Ventolin HfaAlbuterol Sulfate31$1,713

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta$147$188,832292 claims
Boehringer IngelheimOfev, Spiriva Respimat$134$156,01945 claims
Actelion Pharmaceuticals US, Inc.Opsumit$138$137,40911 claims
AstraZenecaBreztri Aerosphere, Symbicort$289$115,761219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 393 pulmonary disease providers in North Carolina.

Other pulmonary disease in Shallotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →